Based on our co-immunoprecipitation studies in CLL cells treated with BH domain antagonists ex vivo (Figure 2), we suggest that proapoptotic protein swapping by the upregulated antiapoptotic proteins prevented the activation of Bax/Bak proteins in these apoptosis-resistant CLL cells. The gene discussed is BAX; the disease is B-cell chronic lymphocytic leukemia.